Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”
-
By
-
Chengqian Chen
-
Wei Guo
-
Xiaoyu Song
-
Xin Wan
-
Zhaoxia Li
-
Haotian Wang
-
Ou Bai
-
May 29, 2026
-
Clinical Scorecard: Shifts in Treatment Approaches for Hodgkin Lymphoma: Transitioning from 'Cure-Focused' to 'Functional Cure'
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Sensitivity to chemotherapy and radiotherapy; emergence of targeted and immunotherapeutic agents (specific references needed). |
| Target Population | |
| Care Setting | |
Key Highlights
- 5-year survival rates exceed 90% in early-stage patients.
- Long-term remission rates above 75% in advanced-stage disease.
- Emergence of targeted therapies like brentuximab vedotin and PD-1 inhibitors (specific references needed).
- Long-term toxicities from conventional therapies include secondary malignancies and cardiovascular disease (specific references needed).
Guideline-Based Recommendations
Diagnosis
Management
- Incorporate immunotherapy-based regimens as a new standard in frontline treatment (specific references needed).
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with classical Hodgkin lymphoma, including those with relapsed or refractory disease.
Focus on minimizing long-term toxicity while maintaining high cure rates.
Clinical Best Practices
- Adopt risk-adapted treatment strategies (specific references needed).
- Implement biomarker-driven precision stratification (specific references needed).
Related Resources & Content
